(8S)-7-methyl-1,4-dioxaspiro[4.5]decan-8-ol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (8S)-7-methyl-1,4-dioxaspiro[4.5]decan-8-ol
• 化学式: C₉H₁₆O₃
• 分子量: 172.22
• InChiKey: LCTPUJDUSKCUMZ-MQWKRIRWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA<br/>[FR] DÉRIVÉS DE N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE ET DE N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS D'IRAK4 POUR LE TRAITEMENT DE L'ASTHME
  申请人：ASTRAZENECA AB

  公开号：WO2022122876A1

  公开（公告）日：2022-06-16

  The present application relates to a compound of Formula (A),wherein R1 is selected from Formula (II) and Formula (III) and R2 is selected from Formula (IV), Formula (V) and Formula (VI) as IRAK4 inhibitors for use in methods of treatment of e.g. asthma and chronic obstructive pulmonary disease (COPD), cancer, inflammatory diseases, and autoinflammatory/autoimmune diseases such as e.g. systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjogren's syndrome, systemic sclerosis, gout, endometriosis, atopic dermatitis and psoriasis. Preferred compounds of the present invention are e.g.: • N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2H-indazole-5- carboxamide, • N-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2H-indazole-5- carboxamide, • N-(imidazo[1,2-b]pyridazin-3-yl)-1-azaspiro[4.5]decan-8-yl-2H- indazole-5-carboxamide, and • N-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-azaspiro[4.5]decan-8-yl-2H- indazole-5-carboxamide derivatives. An exemplary compound of the present invention is e.g. N- (imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-((5r,8r)-1-methyl-2-oxo-1- azaspiro[4.5]decan-8-yl)-2H-indazole-5-carboxamide (Example 1): Formula (VII).

  本申请涉及一种化合物，其化学式为(A)，其中R1从化学式(II)和化学式(III)中选择，R2从化学式(IV)、化学式(V)和化学式(VI)中选择，作为IRAK4抑制剂用于治疗哮喘和慢性阻塞性肺疾病(COPD)、癌症、炎症性疾病以及自身免疫性疾病，如系统性红斑狼疮、类风湿性关节炎、肌炎、干燥综合症、系统性硬化症、痛风、子宫内膜异位症和银屑病等。本发明的优选化合物包括：•N-(咪唑并[1,2-b]吡嗪-3-基)-1-环己基-2H-吲唑-5-羧酰胺、•N-(吡唑并[1,5-a]嘧啶-3-基)-1-环己基-2H-吲唑-5-羧酰胺、•N-(咪唑并[1,2-b]吡嗪-3-基)-1-氮杂螺[4.5]癸烷-8-基-2H-吲唑-5-羧酰胺和•N-(吡唑并[1,5-a]嘧啶-3-基)-1-氮杂螺[4.5]癸烷-8-基-2H-吲唑-5-羧酰胺衍生物。本发明的一种示例化合物是N-(咪唑并[1,2-b]吡嗪-3-基)-6-甲氧基-2-((5r,8r)-1-甲基-2-氧代-1-氮杂螺[4.5]癸烷-8-基)-2H-吲唑-5-羧酰胺(实例1)：化学式(VII)。
• 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES
  申请人：Wisconsin Alumni Research Foundation

  公开号：EP2768803A1

  公开（公告）日：2014-08-27
• [EN] 2-METHYLENE-VITAMIN D ANALOGS AND THEIR USES<br/>[FR] ANALOGUES DE 2-MÉTHYLÈNE-VITAMINE D ET LEURS UTILISATIONS
  申请人：WISCONSIN ALUMNI RES FOUND

  公开号：WO2013059021A1

  公开（公告）日：2013-04-25

  This invention discloses 2-methylene- vitamin D analogs of formula ( I) (wherein R and X are as defined in claim 1 ), and specifically (20S)-25- hydroxy-2-methylene- vitamin D3 and (20R)-25-hydroxy-2-mcthylene-vitamin D3, as well as pharmaceutical uses therefor, These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti¬ cancer agent especially for the treatment or prevention of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. These compounds also have relatively high calcemic activities evidencing USC in the treatment of bone diseases. Formula (I).